9/26/2013 10:06:33 AM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price of $4.10 per share for aggregate gross proceeds of $45.1 million, prior to underwriting discounts and offering expenses. The company has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares to cover over-allotments, if any. The offering is expected to close on or about October 1, 2013, subject to satisfaction of customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by